Greetings,

MedSpan is a market research firm based in Illinois. Our client is a drug company that is developing a new therapy for the treatment of Dupuytren’s disease. This therapy is not currently available on the market.

We are currently conducting a study to understand patients’ reactions to this therapy. All that is required is a 45-minute telephone interview. We will be scheduling interviews for March 23 through April 10, 2009. We will schedule an interview at a time and date that is convenient for you.

In appreciation of your time, we are offering an honorarium of $75.

We are seeking only 25 Dupuytren’s disease patients to participate in our study, so please respond at your earliest convenience. If you are interested, please contact:

John Sanders
Recruiter
jsanders@medspanresearch.com
847.713.8085 (phone) 847.510.0440 (fax)

MedSpan 10 Executive Court South Barrington, IL 60010
www.medspanresearch.com

Feel free to share this invitation with anyone you know who suffers from Dupuytren’s disease.

Sounds interesting... I wonder what the pharmaceutical objective is.

They don't say which drug company they are working for. That's a red flag. They want information you might not want to be made public. I got this pitch in my E-mail and dumped it. Be very carefull

Thank you Mary. What questions did they ask you? I am all for new therapys but I'm a physician myself and this didn't sound right. I have helped patients into reseach protocols and this just sounded to vague compaird to the real ones I've worked with.

Colleen MD

I spent a pleasant 45 minutes being interviewed by the head of Medspan Research on Tuesday morning. I was given an 800 number to call and a website to log onto so I could see a simple diagram. Nothing graphic as I had initially feared. Robert wanted to know about my dups experience, how it has impacted my life, my NA with Dr. Pess in December of 2006, & how things have gone since then. He sought my opinion of a proposed 3 step treatment diagram for an unnamed injectable product referred to only as "product DD". He was a thorough interviewer and a good listener who summarized my statements to make sure he was hearing me correctly. I assumed it was Xiaflex although he could not verify that. He informed me that a representative from the company would be listening in. So I took it as an opportunity to share my hopes & concerns about making sure that when it comes on the market that it will be affordable for those who can use it as a treatment mode. As a retiree, I can use the $75 honorarium when it arrives in several weeks.

Edited 03/28/09 04:25